PRIOR AUTHORIZATION CRITERIA

BRAND NAME*
(generic)
(diclofenac sodium gel 3%)

Status: CVS Caremark Criteria
Type: Initial Prior Authorization
Ref # 621-C

* Drugs that are listed in the target drug box include both brand and generic and all dosage forms and strengths unless otherwise stated. OTC products are not included unless otherwise stated.

FDA-APPROVED INDICATIONS
Diclofenac sodium gel 3% (generic Solaraze Gel) is indicated for the topical treatment of actinic keratoses (AK). Sun avoidance is indicated during therapy.

COVERAGE CRITERIA
The requested drug [diclofenac sodium gel 3 percent (generic Solaraze)] will be covered with prior authorization when being prescribed for the treatment of actinic keratoses (AK).

Quantity limits apply.

RATIONALE
The intent of the criteria is to provide coverage consistent with product labeling, FDA guidance, standards of medical practice, evidence-based drug information, and/or published guidelines. Diclofenac sodium gel 3% is indicated for the topical treatment of actinic keratoses (AK).

Diclofenac sodium gel 3% is applied to lesion areas twice daily. Normally 0.5 grams of gel is used on each 5 cm x 5 cm lesion site. Up to three major body areas were studied in any patient. A major body area was defined as one of five 5 cm x 5 cm regions: scalp, forehead, face, forearm and hand.

Diclofenac sodium gel 3% is available in tubes of 100 grams. 100 grams should be sufficient to adequately cover three areas at a size of 5 cm x 5 cm for 30 days.

The recommended duration of therapy is from 60 days to 90 days. The duration of approval will be 3 months.

REFERENCES
CRITERIA FOR APPROVAL

1. Is the requested drug [diclofenac sodium gel 3 percent (generic Solaraze)] being prescribed for the treatment of actinic keratoses (AK)?
   - Yes
   - No

2. Does the patient require more than the plan allowance of 100 grams per month?
   - Yes
   - No

[Notes: If yes, then deny and enter a partial approval for 100 grams per 25 days of diclofenac sodium gel 3 percent.]

Guideline for Approval

<table>
<thead>
<tr>
<th>Duration of Approval</th>
<th>3 Months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Set 1</td>
<td></td>
</tr>
<tr>
<td>Yes to Question(s)</td>
<td>No to Question(s)</td>
</tr>
<tr>
<td>1</td>
<td>2</td>
</tr>
</tbody>
</table>

Mapping Instructions

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
<th>DENIAL REASONS – DO NOT USE FOR MEDICARE PART D</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Go to 2</td>
<td>Deny</td>
<td>You do not meet the requirements of your plan. Your plan covers this drug when you have actinic keratoses (AK). Your request has been denied based on the information we have. [Short Description: No approvable diagnosis]</td>
</tr>
<tr>
<td>2. Deny</td>
<td>Approve, 3 Months, 100 grams/25 days, 300 grams/75 days</td>
<td>You have requested more than the maximum quantity allowed by your plan. Current plan approved criteria cover up to 100 grams/month of diclofenac sodium gel 3 percent. You have been approved for the maximum quantity that your plan covers for a duration of 3 months. Your request for additional quantities of the requested drug and strength has been denied. [Short description: Over max quantity]</td>
</tr>
</tbody>
</table>

*The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.*